Clinical Trial Update: VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating VX15/2503 in combination with ipilimumab or nivolumab for head and neck squamous cell carcinoma; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• OPDIVO (nivolumab)
• VX15/2503
• Yervoy (ipilimumab)

Snippet

Sponsor: Emory University | Conditions: Squamous Cell Carcinoma of the Head and Neck | Phase 1 | Status: RECRUITING